TABLE 4.
Comparison of pharmacokinetics of single doses of (+)-calanolide A by dose and by subject gender
| Dose cohort (n) | Mean ± SEM
|
|||||
|---|---|---|---|---|---|---|
| Dose (mg/kg) | Cmax (ng/ml) | Tmax (h) | AUC (ng · h/ml) | t1/2 (h) | CL/F (ml/min/kg) | |
| 200 mg | ||||||
| All (8) | 2.6 ± 0.1 | 454 ± 127 | 5.2 ± 1.6 | 2,690 ± 680 | CNCa | 29.8 ± 9.8 |
| Males (4) | 2.4 ± 0.2 | 374 ± 180 | 4.5 ± 2.6 | 2,149 ± 894 | CNC | 38.1 ± 18.4 |
| Females (4) | 2.8 ± 0.1 | 534.5 ± 196.6 | 5.9 ± 2.2 | 3,230 ± 1,079 | CNC | 21.6 ± 8.1 |
| 400 mg | ||||||
| All (12) | 5.4 ± 0.2 | 1,721 ± 222 | 3.5 ± 0.6 | 9,149 ± 1,273 | CNC | 14.3 ± 3.6 |
| Males (6) | 4.9 ± 0.1 | 1,476 ± 366 | 2.5 ± 0.6 | 7,530 ± 2,192 | CNC | 18.9 ± 6.8 |
| Females (6) | 5.8 ± 0.2 | 1,966 ± 243 | 4.4 ± 1.1 | 10,768 ± 1,130 | CNC | 9.7 ± 1.3 |
| 600 mg | ||||||
| All (12) | 8.6 ± 0.3 | 2,168 ± 296 | 4.4 ± 1.2 | 11,808 ± 1,096 | CNC | 16.5 ± 4.8 |
| Males (6) | 8.2 ± 0.3 | 1,936 ± 295 | 4.2 ± 0.9 | 11,739 ± 893 | CNC | 12.2 ± 1.3 |
| Females (6) | 9.0 ± 0.5 | 2,400 ± 526 | 4.7 ± 2.4 | 11,878 ± 2,117 | CNC | 20.9 ± 9.6 |
| 800 mg | ||||||
| All (12) | 10.8 ± 0.6 | 2,813 ± 198 | 2.4 ± 0.4 | 18,821 ± 1,384 | 19.8 ± 1.2 | 10.0 ± 0.8 |
| Males (6) | 9.3 ± 0.4 | 2,673 ± 277 | 2.3 ± 0.4 | 15,729 ± 1,317 | 18.3 ± 2.3 | 10.2 ± 1.1 |
| Females (6) | 12.4 ± 0.7 | 2,952 ± 297 | 2.5 ± 0.8 | 21,912 ± 1,693 | 21.0 ± 1.2 | 9.8 ± 1.2 |
a
CNC, could not be calculated.